Pfizer Inc.

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors head into next week with a bit of improved visibility after tariff exemptions were spelled ...

The AdComm outcome isn't just good news for Pfizer, which is looking to expand its blockbuster further after December's psoriatic arthritis nod. It's also good news for would-be competitors in the JAK inhibitor class, such as AbbVie's upadacitinib and Gilead's filgotinib, Porges figures. “We regard this vote as ...

US regulatory advisors are backing use of Pfizer's JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC). The US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee voted unanimously (15-0) in favour of marketing clearance for the drug in this ...

Pfizer Inc. announced a positive outcome from today's U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting. The GIDAC met to discuss Pfizer's supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), which is currently under review by the ...

In fact, Pfizer is exclusively responsible for the discovery and development of the rheumatoid arthritis drug Xeljanz and assumed all the risk in applying insights from the publicly available, basic research results of an outstanding researcher at the National Institutes of Health to help advance an existing ...

Pfizer has been slowly but surely backing out of its $635 million armed antibody tech deal with CytomX in the last few months, and during the biotech's financials posted late yesterday, the final nail was drilled into this fruitless pact. In 2013, the big pharma teamed up with the South San Francisco-based ...

Pfizer (PFE) is the second largest major drug manufacturer by market capitalization. Out of 28 competitors, they have the 9th highest PE and 16th highest forward PE. But these numbers are skewed; more than half of the major drug manufacturers have current or projected losses, giving them a current and ...

The South San Francisco-based biotech says that Pfizer $PFE notified them yesterday that they are dropping out of the Probody deal, discarding its latest two targets after dumping the first on EGFR and never going after the fourth. The deal, which started out with a $25 million upfront payment and a large ...

Chicago, IL – March 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer Inc. PFE, Verizon ...

Pfizer (PFE) reported slightly higher-than-expected fourth-quarter results and issued 2018 tax-rate guidance 500 basis points below our expectations, which will likely lead to an increase in our fair value estimate relatively close to the current stock price. Pfizer's largely flat total revenue in the quarter despite ...

England's National Health Service (NHS) might be able to reclaim £502 million in drug costs from Pfizer if the pharma giant exhausts all legal avenues to maintain its patent on the pain medication pregabalin. Prescriptions of Pfizer's branded version of the drug – Lyrica – increased by 25% after doctors ...

Federated Investors turns 63 on Oct. 1 and the financial-services giant, with about $400 billion in assets under management, has gone a lot further than most ventures formed by high-school buddies. Federated (ticker: FII) is also the home of one of the market's most respected observers, Stephen Auth, chief ...

In late February 2018, an article posted to “alternative health” blog HealthNutNews.com began circulating, leading readers to believe that the vice president of the pharmaceutical giant Pfizer had “blown the whistle” on Gardasil, a vaccine that protects against human papillomavirus, an umbrella term for ...